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Abstract
The presence of normal tissues in the irradiated volume limits dose escalation during pelvic radiotherapy (RT) for prostate cancer.
Supine and prone positions on a belly board were compared by analyzing the exposure of organs at risk (OARs) using intensity
modulated RT (IMRT). The prospective trial included 55 high risk, localized or locally advanced prostate cancer patients,
receiving definitive image-guided RT. Computed tomography scanning for irradiation planning was carried out in both positions.
Gross tumor volume, clinical and planning target volumes (PTV) and OARs were delineated, defining subprostatic and
periprostatic rectal subsegments. At the height of the largest antero-posterior (AP) diameter of the prostate, rectal diameters
and distance from the posterior prostate wall were measured. IMRT plans were generated. Normal tissue exposure and structure
volumes were compared between supine and prone plans using paired t-test. In the volumes of the prostate, PTV, colon and small
bowel, no significant differences were found. In prone position, all rectal volumes, diameters, and rectum–prostate distance were
significantly higher, the irradiated colon and small bowel volume was lower in dose ranges of 20–40 Gy, and the exposure to all
rectal segments was more favorable in 40–75 Gy dose ranges. No significant difference was found in the exposure of other
OARs. Prone positioning on a belly board is an appropriate positioning method aiming rectum and bowel protection during
pelvic IMRTof prostate cancer. The relative reduction in rectal exposure might be a consequence of the slight departure between
the prostate and rectal wall.
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Introduction
Prostate cancer is the second most common malignancy
worldwide [1]. Its prognosis has improved as a result of
adjuvant androgen deprivation therapy and the escalated
dose, and the efficacy of radiotherapy (RT) [2].
Therefore, pelvic irradiation including the prostate, sem-
inal vesicles, and lymphatic regions is an integral com-
ponent of high-risk [3], organ-confined, and locally ad-
vanced prostate cancer management.
Although RT is getting more targeted, the tolerance of nor-
mal tissues limits dose escalation and tumor control probability,
and makes the incidence of acute and chronic gastrointestinal
(GI) morbidity higher, aggravating the co-existing urological,
sexual, and psychological problems of the increasing number
of cancer survivors [4]. The phenomena of GI injury secondary
to RTare described as pelvic radiation disease (PRD) [5]. Acute
PRD, occurring during or shortly after RT, presents in abdom-
inal–anorectal pain, lack of appetite, nausea, vomiting,
bloating, diarrhea, and rectal bleeding. Chronic complications
developing between 1.5 and 6 years after the completion of
pelvic RT may manifest as anorexia, lactose intolerance, mal-
absorption, fistula formation, bowel obstruction, perforation,
and fecal incontinence [6]. The symptoms depend on the de-
gree and extent of the tissue damage [7] and have a significant
adverse effect on the patient’s quality of life [8]. The most
important factors related to the probability of the complications
are the total dose of RT delivered to the pelvic organs, the
applied regime, the size of the treatment fields, the presence
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of radiation implants, concurrent chemotherapy, and the vol-
ume of the bowel irradiated [7].
The irradiated bowel volume can be minimized by surgical
and non-surgical methods [9]. Surgical means include pelvic
reconstruction, reperitonealization of the pelvic floor, place-
ment of an omental sling, and the inserting of a synthetic pros-
thesis under the small intestine. Radiotherapeutic techniques
embrace among others the use of intensity modulated (IM)
and image-guided (IG) RT, adaptive irradiation, a shrinking
field, modified fractionation schemes, endorectal balloons, tis-
sue spacers, bladder distension, and optimal patient position.
The purpose of our study was to assess whether a supine or
prone position on a belly board, applying IMRT technique,
results in the reduction of the radiation dose to organs at risk
(OARs), primarily the rectum, colon, and small intestines dur-
ing pelvic RT of prostate cancer patients.
Materials and Methods
Patient Population
The prospective analysis included patients with a histologically
confirmed, high risk [10], localized or locally advanced (2009
TNM classification [11] stage T2–4 N0–1 M0) prostate cancer
graded according to the Gleason score system [12], receiving a
definitive pelvic RT at the Department of Oncotherapy,
University of Szeged, Hungary. The tumor stage assessment
was based on the findings of thoracic computed tomography
(CT), abdominal and pelvic CT and magnetic resonance imag-
ing (MRI), and whole-body bone scintigraphy. Clinical and
pathological data were extracted from the patient files.
Patient Positioning and Computed Tomography
Scanning
Patients were positioned on the supine and prone pelvis mod-
ules of the All in One (AIO) Solution (ORFIT, Wijnegem,
Belgium) system. In supine pose, the patient was positioned
with bent knees, and the genitalia were distracted with extrud-
ed polystyrene blocks. In prone position, a belly board was
applied to allow the abdomen to extend into its aperture, and a
polystyrene wedge was placed between the buttocks. For im-
mobilization a six-point thermoplastic mask fixation
(Pelvicast system, ORFIT, Wijnegem, Belgium) was
employed. All patients underwent five-millimeter slice-incre-
ment topometric CT scanning in both positions from the dia-
phragm to the level of 10 cm below the femoral necks, using a
Somatom Emotion 6 CT Simulator (Siemens, Erlangen,
Germany). CT scanning was prepared with full bladder ac-
cording to our internal protocol, and following an antiflatulent
diet for at least 7 days prior and during RT delivery.
Target and Critical Structure Delineation
The gross tumor volume (GTV), clinical target volume
(CTV), planning target volume (PTV), and OARs were delin-
eated in the ARIA Oncology Information System (Varian
Oncology Systems, Palo Alto, CA, USA) in both positions
by radiation oncologists and reviewed by an experienced ra-
diologist. The prostate was contoured as GTVp, the proximal
thirds, or in case of involvement, the full extension of the
seminal vesicles were contoured as GTVvs, and pathologic
lymph nodes, if present, as GTVN, considering MRI records.
CTVN included the parailiac, upper subaortic presacral and
obturator lymph nodes, contoured according to the RTOG
GU Radiation Oncology Specialists Reach Consensus [13].
PTVp included GTVp with a 10 mm margin along the
supero-inferior, left–right axis, in anterior direction and
7 mm in posterior direction. PTVpvs was defined as the com-
bination of GTVp and GTVvs with a safety margin of 10 mm
and 15 mm in posterior direction and any other directions,
respectively. PTV was determined as PTVpvs, a 7 mm margin
around CTVN and 10 mm around GTVN, if present. The rec-
tum, large and small intestines, urinary bladder, femoral
heads, and bony structures were outlined as OARs. The rec-
tum was defined from the ischial tuberosities to the sigmoid
flexure, but at least 2 cm above PTVpvs. Each rectal section,
the whole rectum (R), the segment at the height of the prostate
(R1), and R1 + 10 mm along the supero-inferior axis (R2)
were individually delineated. Large and small bowel volumes
contained all identifiable segments. The bladder was delineat-
ed from the apex to the dome [14].
Rectal Extension and Rectum–Prostate Distance
Measurement
At the height of the largest antero-posterior (AP) diameter of
the prostate, rectal diameters along the AP and left–right axis
were defined, and perpendicular lines were created from the
center and lateral edges of the back wall of the prostate to the
outer anterior rectal wall in both supine and prone positions
(Fig. 1). Two independent radiation oncologists performed
rectum–prostate distance measurements, both of them twice.
Intensity-Modulated Radiotherapy Planning
and Dosimetric Analysis
IMRT planning was performed using the Eclipse treatment
planning system (Varian Oncology Systems, Palo Alto, CA,
USA). The prescribed doses were 45 Gy to the center of the
PTV (1.8 Gy/day, 5 days/week), 14 Gy of the PTVpvs and
18 Gy of PTVp, both delivered in daily 2 Gy fractions, 5 days
per week. OAR dose constraints were determined as the fol-
lowing [13]: V55Gy (bladder) ≤ 50%, V70Gy (bladder) ≤ 30%; V50Gy
(rectum) ≤ 50%, V70Gy (rectum) ≤ 20%; V50Gy (colon) ≤ 50%, V70Gy
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(colon) ≤ 20%; V52Gy (small intestine) = 0%; V50Gy (femoral heads) <
5%. For the coverage of the PTV sliding window IMRT plans
were designed in both positions with a seven-field beam ar-
rangement using 6 MV photon beam quality, consisting copla-
nar beam directions as the following: in prone position 0°,
136.1°, 208.3°, 258.7°, 101.7°, 306.1° and 55.2°, in supine
position 0°, 38.2°, 98°, 142°, 215.7°, 269.5° and 318.2°. For
the PTVpvs and PTVp volumetric modulated arc therapy
(VMAT) plans were generated in both positions using 6 MV
photon beam quality, 181°–179° and 179°–181° gantry angles
and 30° and 15° collimator angles, respectively. IMRT plans
were created to obtain a 95% coverage of the PTV with the
95% isodose curve. The highest priority was PTV coverage,
and the second one was the sparing of OARs. Planning assis-
tant contours of the PTV, PTVpvs, and PTVp were designed
with uniform margins of 15 mm, 30 mm, 40 mm, and 50 mm
in both positions. Dose-volume histograms were calculated for
all defined volumes. Data of mean volumes of the contoured
structures, mean absolute volumes of the small bowel and co-
lon receiving 20–50 Gy, mean relative volumes of the rectal
segments receiving 30–75 Gy and of the bladder receiving 30–
70 Gy doses and mean of doses regarding PTV D95, PTVpvs
D95, and PTVp D95 were collected.
Radiation Treatment and Image-Guidance
Irradiation was carried out by using a Varian TrueBeamSTx
(Varian Oncology Systems, Palo Alto, CA, USA) in prone po-
sition. Image-guidance was based on daily kV-cone beam CT
(CBCT) scanning of the pelvis prior to treatment, using the
standard mode settings: 125 kV, 80 mA, 13 ms, and half-fan
bowtie filter. An automatic match algorithm was used to match
the bony structures displayed on the planningCTand theCBCT.
Statistical Analysis
Data were reported as mean ± SD, mean ± SE or median
values. The difference between the volumes and doses in
supine and prone position was analyzed with the paired sam-
ples t-test. Intraobserver and interobserver variabilities were
calculated from the mean of distances by using correlation
analysis, given a correlation coefficient (r). SPSS 20.0 for
Windows (SPSS Inc., Chicago, IL, USA) was used to perform
the analysis. A p value <0.05 was considered significant.
Results
Patient Population
Between October 13, 2016 and October 11, 2017, 55 patients
with high risk localized or locally advanced prostate cancer
were administered definitive pelvic lymph node RT. Patients
belonged to the elderly age group with a median [range] age of
65.60 [53.33–83.49] years, and they were mostly overweight
showing a median [range] value of body mass index of 26.96
[19.37–41.62] kg/m2. More than three-quarters of them had a
cardiovascular co-morbidity, and one-third of them were
smokers. All the patients had stage T2–4 N0 M0 tumor with
a Gleason score ≥ 7 and a prostate specific antigen (PSA) level
at the time of the diagnosis established >5 ng/ml. Most of the
patients received a 6-month course of luteinizing hormone-
releasing hormone analogue and antiandrogen (total androgen
blockade, TAB) endocrine therapy, launched before the com-
mencing of RT. The relevant patient and tumor characteristics
are shown in Table 1.
Structure Volumes and Rectal Extension
No significant differences were found between prone and su-
pine positions in the volumes of the GTVp, PVS, PTV, colon,
small bowel, and urinary bladder. All rectal volumes (R, R1
and R2) were significantly higher in prone position. The higher
SD values of mean bladder volumes in the two positioning
methods might be the consequence of pre-existing urinary
symptoms, such as incontinence. At the height of the largest
Fig. 1 Rectal extension and rectum–prostate distance measurement: At
the height of the largest antero-posterior diameter of the prostate perpen-
diculars were created from the center and both lateral edges of the
posterior prostate wall to the anterior rectal wall in both prone (a) and
supine (b) positions. Larger rectal diameters in prone, smaller in supine
position in case of the same patient at the same time
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AP level of the prostate, both the AP and the lateral rectal
diameters were significantly higher in prone position (Table 2).
Rectum–Prostate Distance
The rectum–prostate distance measured from the center
of the rear prostate wall to the outer anterior rectal wall
was significantly higher in prone position. No signifi-
cant differences in the distance values measured from
the left and right edges of the posterior prostate wall
were found. Both intraobserver and interobserver vari-
abilities showed close correlation (Table 3).
Normal Tissue Doses
A prone position with the additional use of a belly board led to
a significant decrease in the absolute volumes receiving doses
greater than 20 to 40 Gy in the small intestine and the colon;
however, the difference between the volumes receiving 50 Gy
was not significant (Table 4). In dose ranges of 40 to 75 Gy,
the exposure of all rectal segments was more favorable in
prone position. The relative volume receiving 30 Gy dose
was lower in respect of R1 segment; nonetheless, the differ-
ence was not significant. The relative exposed volume of the
urinary bladder, femoral heads, and bony structures was in
accordance with the dose constraints. No significant differ-
ence was found between the positioning methods (Table 5).
Planning Target Volume Coverage
PTV coverage did not differ significantly between the two
positions (PTV D95 - mean of dose 43.01 vs. 43.00 Gy, SD
0.26 vs. 0.26 in prone vs. supine position, respectively, p =
0.782; PTVpvs D95 - mean of dose 13.36 vs. 13.35 Gy, SD
0.07 vs. 0.07 in prone vs. supine position, respectively, p =
0.591; PTVp D95 - mean of dose 17.16 vs. 17.15 Gy, SD 0.09
vs. 0.07 in prone vs. supine position, respectively, p = 0.435).
Discussion
Clinically localized high-risk prostate cancer frequently
shows micrometastatic spreading to the pelvic lymph
nodes; therefore, RT and three years of androgen suppress-
ing endocrine treatment are the standard of care. Dose es-
calation to the prostate even to 80–86.4 Gy reduces bio-
chemical failure and the appearance of distant metastases
[2]. However, survival data are controversial regarding field
size [2]. There is no consensus recommendation for patient
selection for pelvic RT in this population, considering the
increased exposure of OARs and toxicity. 90% of patients
treated with pelvic RT develop permanent alterations in
bowel habits [8], 50% of them complain about adverse
changes in life quality [15], and 20–40% of them assess
this impact as moderate or severe [16]. The small intestine,
the rectum, and to a lesser extent, the colon are dose-
Table 1 Patient and tumor characteristics
Tumor and patient characteristics Number of patients (%)
Number of patients 55
Concurrent cardiovascular disease 44 (80.00)
History of smoking 18 (32.73)
Clinical stages
T2 41 (74.55)
T3 12 (21.82)
T4 2 (3.64)
Gleason scores
7 27 (48.21)
8 5 (9.09)
9 19 (33.93)
10 4 (7.14)
PSA levels on establishing the diagnosis (ng/ml)
10 > x > 5 13 (23.21)
20 > x ≥ 10 9 (16.36)
≥ 20 33 (58.93)
Endocrine treatment 49 (89.09)
Table 2 Volumes of the delineated structures and rectal diameters in
prone and supine positions
Structure Position Mean volume
(cm3)
Standard
deviation (SD)
p
value
GTVp Prone 130.11 49.13 0.217
Supine 133.28 50.87
PVS Prone 188.77 58.19 0.748
Supine 190.23 58.20
PTV Prone 1123.54 138.90 0.282
Supine 1130.98 146.66
Whole rectum
(R)
Prone 155.13 105.26 <0.001
Supine 95.61 45.89
Rectal
subsegment
R1
Prone 50.32 31.84 <0.001
Supine 34.76 23.64
Rectal
subsegment
R2
Prone 74.37 41.51 <0.001
Supine 50.78 27.64
Colon Prone 580.32 299.38 0.486
Supine 604.37 337.12
Small bowel Prone 812.93 354.25 0.373
Supine 772.71 353.21
Urinary bladder Prone 184.18 117.13 0.403
Supine 192.40 112.56
Rectal diameter Position Mean diameter
(mm)
Standard error
(SE)
p value
AP Prone 50.60 2.20 <0.001
Supine 36.70 1.50
Lateral Prone 43.80 2.60 0.003
Supine 35.90 1.80
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limiting organs, tolerating a 50–60 Gy dose at conventional
fractionation [17, 18]. Normal tissue complication probability
(NTCP) studies suggest that the small intestine volume receiv-
ing 15 and 45 Gy (V15 and V45) is a relevant parameter for GI
morbidity [19, 20]. According to the review of Fiorino et al.
[21], keeping V70 and V75 to <25 and 5%, respectively, results
in a decrease in the development of late rectal bleeding.
Moderate dose volumes, such as V40 and V50 are predictive
for chronic late incontinence [22] and are also important in
developing rectal bleeding [21]. The dosimetric analysis [23]
of the anatomical subregions showed that rectal bleeding is
associated with V70 of the anorectal region, fecal inconti-
nence with V15 of external sphincter, and V55 of the
iliococcygeal muscle, whereas stool frequency with V40 of
the levator ani and V45 of the iliococcygeal muscle. In the
prospective study of Dréan et al. [24], rectal subregions at risk
have been delineated, and the authors have found that the
exposure of the subprostatic anterior hemirectum and the up-
per part of the anal canal was 4 Gy higher in patients devel-
oping rectal bleeding.
Table 3 Rectum–prostate distance and intraobserver and interobserver variability correlation in prone and supine positions
Distance Position Mean (mm) Standard error
(SE)
p value Intraobserver variability – Correlation coefficient (r) Interobserver variability –
Correlation coefficient (r)
Examiner 1 Examiner 2
Left lateral Prone 6.50 0.40 0.062 0.92 0.90 0.89
Supine 5.70 0.40
Mediosagittal Prone 2.80 0.30 0.026 0.86 0.89 0.95
Supine 2.20 0.30
Right lateral Prone 5.90 0.40 0.173 0.80 0.74 0.78
Supine 5.40 0.40
Table 4 Small intestine and colon exposure in prone and supine
position
Organ at
risk
DVH
parameter
Position Mean
volume
(cm3)
Standard
deviation (SD)
p
value
Small
intestine
V20 Gy Prone 79.85 89.83 <0.001
Supine 170.34 103.62
V30 Gy Prone 36.74 51.24 <0.001
Supine 84.55 63.01
V40 Gy Prone 16.99 26.08 <0.001
Supine 32.91 31.35
V50Gy Prone 0.16 1.06 0.398
Supine 0.33 1.54
Colon V20 Gy Prone 122.43 74.52 <0.001
Supine 181.22 109.48
V30 Gy Prone 84.09 57.17 <0.001
Supine 121.21 73.36
V40 Gy Prone 53.23 44.20 0.043
Supine 63.19 44.89
V50 Gy Prone 2.06 4.02 0.627
Supine 1.81 3.62
Table 5 Exposure of rectal segments and urinary bladder in prone and
supine positions
Organ at risk DVH
parameter
Position Mean
relative
volume
(%)
Standard
deviation
(SD)
p
value
Whole rectum V30Gy Prone 106.40 118.98 0.296
Supine 89.60 7.46
V40Gy Prone 65.79 14.96 <0.001
Supine 78.58 10.14
V50Gy Prone 35.51 13.83 <0.001
Supine 48.38 12.29
V60Gy Prone 17.45 8.18 <0.001
Supine 24.04 9.11
V70Gy Prone 7.57 4.10 <0.001
Supine 10.43 4.97
V75Gy Prone 3.67 2.61 0.021
Supine 4.58 3.19
Rectal
subsegment
R1
V30 Gy Prone 99.78 0.75 0.735
Supine 99.80 0.61
V40Gy Prone 80.58 13.50 <0.001
Supine 94.95 5.74
V50Gy Prone 52.25 14.18 <0.001
Supine 68.55 10.90
V60Gy Prone 32.37 10.90 <0.001
Supine 40.49 10.13
V70Gy Prone 16.51 5.83 <0.001
Supine 20.74 7.14
V75Gy Prone 8.79 4.52 0.099
Supine 9.97 5.67
Rectal
subsegment
R2
V30Gy Prone 99.52 1.21 0.001
Supine 98.61 1.96
V40Gy Prone 78.55 12.66 <0.001
Supine 91.45 6.05
V50Gy Prone 49.40 13.14 <0.001
Supine 64.83 9.89
V60Gy Prone 28.95 9.04 <0.001
Supine 37.43 8.76
V70Gy Prone 13.52 4.75 <0.001
Supine 17.86 5.79
V75Gy Prone 6.82 3.59 0.051
Supine 7.86 4.43
Bladder V30Gy Prone 95.82 7.10 0.657
Supine 95.45 5.13
V40Gy Prone 67.99 18.89 0.687
Supine 68.78 16.13
V50Gy Prone 41.90 16.53 0.982
Supine 41.86 14.84
V60Gy Prone 26.73 11.77 0.235
Supine 25.36 10.62
V70Gy Prone 15.91 7.90 0.276
Supine 14.94 7.31
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Technological advances allowing rectal sparing include
endorectal balloons filled with air or water, reducing the expo-
sure of the posterior rectal wall by moving away the prostate
from it, depending on the volume of the balloons [25].
Bioabsorbable tissue spacers injected into the retroprostatic
fascia also increase the distance between the prostate and the
anterior rectal wall, resulting in significant reduction in both
acute and late GI toxicities [26]. Regarding patient positioning,
Zelefsky et al. [27] and McLaughlin et al. [28] have described
significantly lower rectal doses in prone position, using
3DCRT technique. The results have also been confirmed in
the phase II trial of O’Neil et al. [29] and by Bajon et al. using
tomotherapy [30]. Nevertheless, Baylay et al. [31] have found
supine position more favorable by using larger PTVmargins in
prone position, andKato et al. [32] by applying IMRT in supine
and 3DCRT in prone position. In prone position, the decreased
rectal exposure is a result of the posterior retraction of the
rectum and anterior displacement of the prostate; however,
the accurate mechanism of it is unknown [27, 28, 32].
In the 3D-CRT of rectal malignancies, a prone treatment
position without a belly board compared to a supine posture
results in the reduction of the irradiated small intestine volume
[33]. In case of pelvic malignancies, a larger decrease in the
small intestine exposure can be obtained by the additional use
of a belly board in comparison with both prone position alone
[34, 35] or supine position [36, 37]. The use of IMRT tech-
nique decreases bowel doses by 40–50%, as compared to 3D-
CRT [38, 39]. In case of gynecological and rectal tumors, a
belly board assisted prone position using IMRT results in a
further reduction in the irradiated volume of the small intes-
tine, even in low dose areas [40, 41]. The advantage of the use
of a belly board is also confirmed in postoperatively irradiated
patients [42, 43], which might be the consequence of the sig-
nificantly higher mobilization of the small intestine loops. The
findings of Fu et al. [44] show that the gain of the use of a
belly board is greater if the irradiated small intestine volume
close to the target volume is larger. According to that study, a
prone position on a belly board results in a remarkable de-
crease in the small bowel volume in case of gynecological
malignancies but not in rectal cancer patients. A full bladder
also functions as a natural spacer, transposing the small intes-
tine loops from the pelvis to the abdomen, resulting in a re-
duction in the irradiated small intestine volume [42].
In rectal cancer patients treated with chemo-radiotherapy,
Baglan et al. [19] have demonstrated an explicit relationship
between the volume of the small bowel receiving at least
15 Gy and the degree of acute small intestinal toxicity.
Robertson et al. [45] have proved that a reduction in the small
bowel volume receiving low dose results in a significant de-
crease in the complication rate. Both authors have delineated
the single small intestinal loops. In case of gynecological can-
cer patients treated with pelvic IMRT, Roeske et al. [20] have
detected that drawing the abdominal space, the risk of acute
GI toxicity is five times as little for small bowel volume of
100 cm3 gaining the prescribed 45 Gy dose as of 200 cm3.
According to Gunnlaugsson et al. [46], the former technique is
the recommended contouring method instead of delineating
the abdominal space. Gunnlaugsson et al. have observed
strong correlation between the occurrence of early side effects
and small intestinal loop exposure, and no significant connec-
tion with the peritoneal cavity.
Our study was limited by the lack of delineating the penile
bulb, and the relatively small number of patients involved,
which however was double the number of patients previously
reported. As most papers have described larger intrafraction
prostate and respiratory motion in prone position [11] and lit-
erature data [47] show that a 3 mm PTV margin allows for
CTV to be covered for 99% of cases when daily CBCT is used,
accurate patient repositioning, daily reconstruction of the rec-
tum, prostate safety margins, early toxicity and life quality dur-
ing and after RTwere also evaluated, and found to be similar to
literature data of patients treated in supine position. These
promising results have recently been submitted. Late toxicities
need further examination due to the short follow-up period.
In conclusion, in the pelvic IMRT for prostate cancer, a
prone position on a belly board decreases the irradiated small
bowel volumes even in low dose ranges and contributes to
rectal sparing. The relative dose reduction in the rectal exposure
might be a consequence of the slight departure between the
prostate wall and the rectal wall, as consistent with the litera-
ture, and the increasing volume and diameters of the rectum
generated by the displacement of rectal gases. Considering the
dosimetric advantages, prone position on a belly board could
be recommended for the pelvic IMRT of prostate cancer.
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